





# Dihydroartemisinin + piperazine

Essential medicine status 

Section: [6. Anti-infective medicines](#) > [6.5. Antiprotozoal medicines](#) > [6.5.3. Antimalarial medicines](#) > [6.5.3.1. Antimalarial medicines](#) > Medicines for curative treatment

		<b>EMLc</b>	ATC codes: <b>P01BF05</b>
<b>Indication</b>	Malaria due to Plasmodium falciparum	ICD11 code: <b>1F40</b>	
<b>Medicine type</b>	Chemical agent		
<b>List type</b>	Core (EML) (EMLc)		
<b>Formulations</b>	Oral > Solid > dispersible tablet: 20 mg + 160 mg (phosphate) (EMLc) ; 40 mg + 320 mg (phosphate) (EMLc) Oral > Solid > tablet: 40 mg + 320 mg (phosphate) ; 20 mg + 160 mg (phosphate) ; 60 mg + 480 (phosphate) ; 80 mg + 640 mg (phosphate)		
<b>EML status history</b>	First added in 2017 ( <a href="#">TRS 1006</a> ) Changed in 2025 ( <a href="#">TRS 1064</a> )		
<b>Sex</b>	All		
<b>Age</b>	Also recommended for children		
<b>Therapeutic alternatives</b>	The recommendation is for this specific medicine		
<b>Patent information</b>	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
<b>Wikipedia</b>	<a href="#">Dihydroartemisinin + piperazine</a> 		
<b>DrugBank</b>	<a href="#">Artemimol</a>  , <a href="#">Piperazine</a> 		

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of two new strengths of tablets (60mg + 480 mg and 80 mg + 840 mg) on the EML and EMLc; - the addition of two new strengths of dispersible tablets (20 mg + 160 mg and 40 mg + 320 mg) on the EMLc; - removal of the weight restriction, in recognition that use should be in line with recommendations with WHO guidelines; - to update the listing to include reference to the phosphate salt of piperazine in the formulation description instead of the medicine name.

